CBER to in­dus­try: Nor­mal op­er­a­tions will re­sume in 2023

The FDA’s Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) has de­vot­ed long hours to the pan­dem­ic, with marathon ses­sions churn­ing out guid­ance doc­u­ments and re­views …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER